Verition Fund Management LLC Purchases New Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Verition Fund Management LLC acquired a new stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) in the third quarter, according to its most recent filing with the SEC. The fund acquired 37,006 shares of the company’s stock, valued at approximately $216,000. Verition Fund Management LLC owned approximately 0.07% of Voyager Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of VYGR. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after acquiring an additional 4,098 shares during the period. Intech Investment Management LLC bought a new position in Voyager Therapeutics in the 3rd quarter worth about $74,000. SG Americas Securities LLC purchased a new position in Voyager Therapeutics during the 2nd quarter valued at about $85,000. Victory Capital Management Inc. increased its position in shares of Voyager Therapeutics by 14.5% during the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after buying an additional 1,630 shares during the period. Finally, Hsbc Holdings PLC bought a new stake in shares of Voyager Therapeutics during the second quarter valued at about $128,000. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Stock Up 0.3 %

Shares of VYGR stock opened at $6.27 on Monday. The business has a 50-day moving average price of $6.59 and a two-hundred day moving average price of $7.16. Voyager Therapeutics, Inc. has a 12-month low of $5.19 and a 12-month high of $11.72. The firm has a market cap of $342.53 million, a P/E ratio of 8.83 and a beta of 0.90.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. During the same quarter in the previous year, the company posted ($0.59) EPS. As a group, research analysts expect that Voyager Therapeutics, Inc. will post -0.89 EPS for the current fiscal year.

Insider Activity

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. The trade was a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.53% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

VYGR has been the subject of several recent analyst reports. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Canaccord Genuity Group restated a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Leerink Partners initiated coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price for the company. Finally, Citigroup initiated coverage on Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target on the stock. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $17.00.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.